130723-10-3

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 130722-44-0 5-benzyloxy-3-fluorophenyl bromide 
• 100-51-6 benzyl alcohol 
• 461-96-1 3,5-difluorobromobenzene 
• 130723-09-0 4-(5-fluoro-3-hydroxyphenyl)-4-methoxy-3,4,5,6-tetrahydro-2H-pyran 

Downstream Products

• 139368-13-1 4-(3-hydroxy-5-fluorophenyl)-4-methylthio-3,4,5,6-tetrahydro-2H-pyran 
• 133739-65-8 4-(3-benzyloxy-5-fluoro-phenyl)-4-ethoxy-tetrahydro-pyran 
• 133739-64-7 3-(4-ethoxy-tetrahydro-pyran-4-yl)-5-fluoro-phenol 
• 167758-68-1 4-(3-fluoro-5-hydroxyphenyl)-4-methylsulfinyl-3,4,5,6-tetrahydro-2H-pyran 
• 167758-69-2 4-(5-hydroxy-3-fluorophenyl)-4-methylsulfonyl-3,4,5,6-tetrahydro-2H-pyran 
• 1345021-15-9 3-(2-(3-fluoro-5-(4-(4-methoxytetrahydropyranyl))phenoxy)ethyl)-6-nitro-1,3,2-benzodithiazolium ylide 1,1-dioxide 
• 1345021-21-7 4-(3-(2-bromoethoxy)-5-fluorophenyl)-4-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 1345021-22-8 4-(3-fluoro-5-(2-mercaptoethoxy)phenyl)-4-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 130723-09-0 4-(5-fluoro-3-hydroxyphenyl)-4-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 130723-11-4 4-<3-fluoro-5-(benzyloxy)phenyl>-4-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 133739-66-9 6-<<3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy>methyl>-1-<(pivaloyloxy)methyl>quinol-2-one 
• 139486-95-6 5-bromo-1,3-dimethyl-6-<<3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy>methyl>benzimidazolin-2-one 
• 139486-96-7 4-[5-fluoro-3-(1,3-dimethyl-2-oxo-2,3-dihydrobenzimidazol-5-ylmethoxy)phenyl]-4-methoxytetrahydropyran 
• 141376-48-9 3-Bromo-6-[3-fluoro-5-(4-methoxy-tetrahydro-pyran-4-yl)-phenoxymethyl]-1-methyl-1H-quinolin-4-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors

3-(4-Bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide (5) was discovered as a new prototype for dual inhibitors of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). Thus, the structure-activity relationships of benzo[1.3.2]dithiazolium ylide 1,1-dioxide skeleton were carried out. The 6-NO2 group played an essential role in the inhibitory activity. In addition, moderate-sized lipophilic substituents at the para-position of the 3-aryl moiety were required for dual COX-2/5-LOX inhibitory activity. Among the identified potent dual inhibitors, 3-(4-tbutylphenyl) derivative 30c (IC50 values of 0.27 μM and 0.30 μM against COX-2 and 5-LOX, respectively) and 3-(4-biphenyl) derivative 30f (IC50 values of 0.50 μMand 0.15 μMagainst COX-2 and 5-LOX, respectively) were the most potent dual COX-2/ 5-LOX inhibitors. Intraperitoneal administration of 30c at 100 mg/kg demonstrated potent acute antiinflammatory activity. As a result, benzo[1.3.2]dithiazolium ylide 1,1-dioxide represented a novel scaffold for the exploitation in developing dual COX-2/5-LOX inhibitors.

TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

New COX-2/5-LOX inhibitors: Apoptosis-inducing agents potentially useful in prostate cancer chemotherapy

The arachidonic acid metabolizing enzymes cyclooxygenase-2 (COX-2) and lipoxygenases (LOXs) have been found to be implicated in a variety of cancers, including prostate cancer. To develop new therapeutic treatments, it therefore seemed interesting to design dual COX-2/5-LOX inhibitors. We report here the synthesis and in vitro pharmacological properties of diarylpyrazole derivatives that have in their structure key pharmacophoric elements to obtain optimal interaction with subsites of active pockets in both enzyme systems. Using a molecular modeling approach, a set of SAR data is proposed, highlighting the importance of the sulfonyl group of one of the aryl moieties in terms of proliferation inhibition and/or apoptosis induction.

Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor

Dual COX-2/5-LO inhibitors are described as potential new therapeutic agents for inflammatory diseases. A surprisingly potent effect of a 5-LO pharmacophoric group on the COX-2 inhibition is presented as well as pharmacological in vitro and in vivo results.

Benzisothiazoles derivatives as inhibitors of 5-lipoxygenase biosynthesis

This invention relates to new heterocyclic compounds which are selective inhibitors of 5-lipoxygenase (5-LO). The new heterocyclic compounds are useful in inhibiting 5-LO per se and in the treatment or alleviation of inflammatory disease or condition, allergy or cardiovascular diseases in mammals wherein the inflammatory disease or condition includes but is not limited to asthma, arthritis, bronchi chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis or osteoa This invention also relates to pharmaceutical compositions useful therefor.

BICYCLIC HETEROCYCLIC DERIVATIVES AS 5-LIPOXYGENASE INHIBITORS

The invention concerns a bicyclic heterocyclic derivative of the formula I wherein Q is an optionally substituted 9-membered bicyclic heterocyclic moiety containing 1 or 2 N's and optionally a further N, O or S heteroatom; A1 is a direct link to X1 or (1-3C)alkylene; X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is optionally substituted phenylene or pyridylene; R1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R2 and R3 together form a group of the formula ?A2?X2?A3? which, together with the carbon atom to which A2 and A3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl or sulphonyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase

PYRAN DERIVATIVES AND THEIR USE AS INHIBITORS OF 5-LIPOXYGENASE

The invention concerns a cyclic ether derivative of the formula I, wherein Ar1 is optionally substituted phenyl, naphthyl or a 9-or 10-membered bicyclic heterocyclic moiety; A1 is a direct link to X1 or (l-3C)alkylene; X1 is oxy, thio, sulphinyl, sulphony

BENZOXAZINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENES

The invention concerns a bicyclic heterocyclic compound of the formula I wherein Q is an optionally substituted 10-membered bicyclic heterocyclic moiety containing 1 or 2 N's and a further O or S heteroatom; A1 is a direct link to X1 or (1-3C)alkylene; X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is optionally substituted phenylene or pyridylene; R1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R2 and R3 together form a group of the formula -A2-X2-A3- which, together with the carbon atom to which A2 and A3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl or sulphonyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase

Thioxo quinoline compounds, composition and method of use

The invention concerns a thioxo heterocycle of the formula I STR1 wherein Q is a 10-membered bicyclic heterocyclic moiety containing 1 or 2 N's which bears 1 or 2 thioxo substituents and which is optionally further substituted; A1 is a direct l

HETEROCYCLIC DERIVATIVES

The invention concerns a heterocyclic derivative of the formula I, or a pharmaceutically-acceptable salt there of. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.